Aspireo Pharmaceuticals

Company Overview

Snapshot

Founded in January 2010, Aspireo Pharmaceuticals operates with 1–10 employees. The company's Somatoprim (DG3173) program was acquired by Cortendo for $30 million in May 2015.

Business overview

Aspireo Pharmaceuticals is a biopharmaceutical company focused on developing novel somatostatin analogs (SSAs) for treating diseases caused by hormone-active tumors, including acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing's disease, and diabetic retinopathy. Its core product, Somatoprim (DG3173), is a proprietary SSA based on a unique amino acid composition and an innovative backbone cyclization technology. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology industries.

Strategic signal

In May 2015, Aspireo Pharmaceuticals' Somatoprim (DG3173) program was acquired by Cortendo for $30 million. This acquisition signals significant validation for Aspireo's novel somatostatin analog technology and its potential in treating hormone-active tumors, demonstrating a successful exit for its core development asset and indicating market interest in differentiated SSA profiles.

Company Intelligence Q&A

What is Aspireo Pharmaceuticals' primary focus?

Aspireo Pharmaceuticals focuses on developing novel somatostatin analogs (SSAs) for treating conditions resulting from hormone-active tumors, such as acromegaly, neuroendocrine tumors, and Cushing's disease.

What is Somatoprim (DG3173)?

Somatoprim (DG3173) is Aspireo Pharmaceuticals' proprietary somatostatin analog, designed with a novel amino acid composition and an innovative backbone cyclization technology for enhanced stability and a differentiated pharmacological profile.

When was Aspireo Pharmaceuticals founded?

Aspireo Pharmaceuticals was founded in January 2010.

What was a significant corporate event for Aspireo Pharmaceuticals in 2015?

In May 2015, Aspireo Pharmaceuticals' Somatoprim (DG3173) program was acquired by Cortendo for $30 million.

Which investor supported Aspireo Pharmaceuticals?

TVM Capital was the sole investor in Aspireo Pharmaceuticals, establishing it as a.